(Q28354163)

2

0 references

J Bock

3

0 references

A Hsu

4

0 references

K Jorga

British Journal of Clinical Pharmacology

5

0 references

language of work or name

English

0 references

publication date

September 2001

0 references

published in

0 references

volume

52

0 references

issue

3

0 references

page(s)

255-64

0 references

cites work

CYP3A gene expression in human gut epithelium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014551

Active human immunodeficiency virus protease is required for viral infectivity

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014551

Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014551

Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014551

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014551

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014551

Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014551

Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014551

Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014551

Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014551

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014551

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014551

Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team.

2 June 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0306-5251.2001.01452.X

Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0306-5251.2001.01452.X

Ritonavir and saquinavir combination therapy for the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0306-5251.2001.01452.X

Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0306-5251.2001.01452.X

Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0306-5251.2001.01452.X

Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population. NV15182 Study Team.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2014551

Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir. NV15107 Study Group

27 November 2018

1 reference

12 December 2020

Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents

1 reference

12 December 2020

Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.

1 reference

12 December 2020

Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy

1 reference

12 December 2020

The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring

1 reference

12 December 2020

10.1046/J.0306-5251.2001.01452.X

Identifiers

DOI

0 references

Fatcat ID

release_xt4viv65a5dondidgt5yloiuwq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xt4viv65a5dondidgt5yloiuwq

24 November 2022